inhibitors
|
Other agents
|
Disease
|
Dosage
|
Clinical trails
|
No Pts
|
Response
|
Reference
|
---|
Tipifarnib
|
Bortezomib
1.0 mg/m2
|
Elderly or relapsed AML
|
300-600 mg bid, ×21d
|
Phase II
|
80
|
CR: 11%
|
[30]
|
Tipifarnib
|
+/- etoposide
|
Elderly untreated AML
| |
Phase II
|
107
|
Safe
|
[31]
|